J&J Files Lawsuit in U.S. to Block Remicade Biosim

May 21, 2017

Reuters

A division of Johnson & Johnson filed a lawsuit in the U.S. District Court of New Jersey to block a copy of its rheumatoid arthritis drug, Remicade, manufactured by Samsung Bioepis Co., according to a Reuters article.

Janssen Biotech Inc. is requesting a preliminary or permanent injunction to block South Korea's Samsung Bioepis' from selling its biosimilar of Remicade and says the company violated three of its patents.

"We have filed a lawsuit against Samsung to investigate whether their biosimilar infliximab infringes on our manufacturing process patents for Remicade," Janssen told Reuters in a statement.

Read the full story